It should be noted that decades of research in the biology of PDAC have led to the discovery of many promising molecular targets for this disease, such as the KRAS mutation that leads to activation of oncogenic signaling, the desmoplastic tumor microenvironment (TME) that facilitates immune evasion, and the altered tumor metabolism that contributes to chemo-resistance [8]. Here, KRAS is linked to neoplasm.